Welcome

The Post-Finasteride Syndrome Foundation’s primary mission is to fund research on the characterization, underlying biologic mechanisms and treatments of post-finasteride syndrome (PFS). Other goals include generating public awareness of PFS and providing support for patients suffering from the condition.

Adverse drug reaction reports worldwide

Adverse drug reaction reports worldwide

PFS research studies published

PFS research studies published

Known suicides worldwide

Known suicides worldwide

Doctors & researchers speaking out

Doctors & researchers speaking out

Nations warning of PFS

Nations warning of PFS

National media reports worldwide

National media reports worldwide

Sources

Patient Services

Connect with other PFS patients

Consult knowledgeable doctors

Report your side effects

Doctors & Researchers Speaking Out

Using finasteride for hair loss is like shooting at sparrows with cannons.

Using finasteride for hair loss is like shooting at sparrows with cannons. The drug.…blocks not only the super hormone but also other hormones that affect thinking and psyche, mood and emotions. Discontinuation of the drug should actually make the hormones work again.…but apparently, something breaks down in some men, in the prostate, in the brain, in the whole organism.

—I Didn’t Want to Go Bald. A Pill the Doctor Gave Me Destroyed My Life (English translation): Die Zeit, Feb. 22, 2018

Michael Zitzmann, MD, Andrology Professor
University of Munster, Germany

We wouldn’t recommend that any man take [finasteride], especially not young men.

We are certainly very cautious, because we see the side effects. We wouldn’t recommend that any man take [finasteride], especially not young men. The longer they take it, the greater the risk of experiencing persistent side effects, including after they’ve stopped.

—Do Anti-Baldness Remedies Make You Impotent? Puls, SRF-TV, May 7, 2018

Doris Mannhard, MD, Urologist
University Hospital Zürich

Blocking 5alpha-reductase by finasteride treatment may have broad consequences for the nervous system.

[W]e have evaluated in male rats the effects of a subchronic treatment with low doses of finasteride.…and the consequences of its withdrawal.…on neuroactive steroid levels…. Interestingly, at the withdrawal, some of these effects persisted, and different changes in neuroactive steroid levels, and in the expression of receptors, were also detected. Altogether these findings suggest that the block of the enzyme 5alpha-reductase by finasteride treatment may have broad consequences for the nervous system.

—Effect of Finasteride, an Inhibitor of the Enzyme 5alpha-Reductase, in the Nervous System: The Journal of Steroid Biochemistry and Molecular Biology, July 2017

Roberto Melcangi, PhD, Head of Neuroendocrinology, Department of Pharmacological and Biomolecular Sciences
University of Milano

FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks.

“Finasteride inhibits Type II 5(alpha)-reductase, which metabolizes testosterone to the potent androgen 5(alpha)-dihydrotestosterone. FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks regarding growth, development and sexual function.”

—FDA response to Merck & Co.’s citizen petition requesting that finasteride be added to the List of Approved Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population: May 2000

Janet Woodcock, MD, Director of the Center for Drug Evaluation and Research
US Food and Drug Administration
More

Daniel M. Stewart: 1976-2014

April 25, 2014 Dear Friends: The Post-Finasteride Syndrome Foundation is saddened to announce the passing of Daniel M. Stewart. The 37-year-old native of Troy, Michigan, and Centertown, Kentucky, died Saturday, April 12, 2014 at his home in Denton, Texas. Daniel, who suffered from post-finasteride syndrome, had recently taken part in a clinical-research study on the […]

Number of Nations Logging onto PFSFoundation.org Rose 29% in 2013

SOMERSET, N.J., Jan. 6, 2014 – The number of nations that logged onto the Post-Finasteride Syndrome Foundation website rose 29 percent in 2013, according to Google Analytics. In all, users in 120 countries outside the United States—or 61 percent of the world (as defined by the 195 nations recognized by the U.S. Department of State)—accessed […]

Reminder: Report PFS Symptoms to FDA MedWatch

SOMERSET, N.J., Oct. 29, 2013 – The Post-Finasteride Syndrome Foundation is reminding PFS patients to report all persistent side effects to the FDA MedWatch program. MedWatch is the U.S. Food and Drug Administration’s system for detecting safety-hazard signals for pharmaceutical products and medical devices. If a signal is detected, the FDA can issue safety alerts, […]

Clinical Study of Post-Finasteride Syndrome Launched at Baylor College of Medicine

SOMERSET, N.J., Aug. 21, 2013 – The Post-Finasteride Syndrome Foundation today announced the funding of a second major clinical study on post-finasteride syndrome (PFS), this one at Baylor College of Medicine (BCM) in Houston, Texas. Titled “Genetic and Epigenetic Studies on Post-Finasteride Syndrome Patients,” the research is being led by Mohit Khera (right), MD, MBA, […]

2013 PFS Foundation Annual Address

Aug. 4, 2013 Dear Friends: When we incorporated the Post-Finasteride Syndrome Foundation in July 2012, our mission was clear: To fund research on the characterization, underlying biologic mechanisms and treatments of PFS while raising public awareness of this often life-altering condition afflicting thousands of men the world over. Now, on the occasion of our one-year […]